Montag & Associates’s Edwards Lifesciences EW Stock Holding History

Montag & Associates’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.68M	Hold	45,996	–	–	0.17%	121
2025 Q4	$3.92M	Sell	45,996 -4,011	-8%	-$329K	0.18%	114
2025 Q3	$3.89M	Hold	50,007	–	–	0.18%	118
2025 Q2	$3.91M	Hold	50,007	–	–	0.19%	112
2025 Q1	$3.62M	Sell	50,007 -60	-0.1%	-$4.29K	0.18%	115
2024 Q4	$3.71M	Sell	50,067 -1,886	-4%	-$132K	0.18%	122
2024 Q3	$3.43M	Hold	51,953	–	–	0.16%	130
2024 Q2	$4.8M	Hold	51,953	–	–	0.24%	88
2024 Q1	$4.96M	Hold	51,953	–	–	0.25%	94
2023 Q4	$3.96M	Sell	51,953 -208	-0.4%	-$14.5K	0.22%	98
2023 Q3	$3.61M	Sell	52,161 -6,178	-11%	-$496K	0.23%	95
2023 Q2	$5.5M	Sell	58,339 -3,471	-6%	-$302K	0.34%	71
2023 Q1	$5.11M	Sell	61,810 -3,178	-5%	-$250K	0.33%	76
2022 Q4	$4.85M	Sell	64,988 -48,014	-42%	-$3.7M	0.32%	78
2022 Q3	$9.34M	Buy	113,002 +8,001	+8%	+$770K	0.65%	36
2022 Q2	$9.98M	Sell	105,001 -457	-0.4%	-$47.3K	0.65%	35
2022 Q1	$12.4M	Sell	105,458 -2,322	-2%	-$260K	0.66%	32
2021 Q4	$14M	Sell	107,780 -538	-0.5%	-$62.8K	0.69%	32
2021 Q3	$12.3M	Buy	108,318 +13,659	+14%	+$1.56M	0.66%	35
2021 Q2	$9.8M	Sell	94,659 -485	-0.5%	-$45.7K	0.52%	46
2021 Q1	$7.96M	Sell	95,144 -3,767	-4%	-$318K	0.45%	62
2020 Q4	$9.02M	Buy	98,911 +4,780	+5%	+$396K	0.55%	51
2020 Q3	$7.51M	Buy	94,131 +2,013	+2%	+$157K	0.61%	45
2020 Q2	$6.37M	Buy	92,118 +1,230	+1%	+$87.4K	0.56%	48
2020 Q1	$5.71M	Buy	90,888 +23,958	+36%	+$1.73M	0.57%	49
2019 Q4	$5.21M	Sell	66,930 -2,280	-3%	-$178K	0.42%	65
2019 Q3	$5.07M	Sell	69,210 -1,569	-2%	-$110K	0.44%	59
2019 Q2	$4.36M	Sell	70,779 -360	-0.5%	-$21.8K	0.39%	64
2019 Q1	$4.54M	Sell	71,139 -180	-0.3%	-$10.3K	0.42%	63
2018 Q4	$3.64M	Sell	71,319 -1,185	-2%	-$60K	0.39%	67
2018 Q3	$4.21M	Sell	72,504 -156	-0.2%	-$7.63K	0.37%	68
2018 Q2	$3.53M	Sell	72,660 -6,642	-8%	-$310K	0.36%	75
2018 Q1	$3.69M	Sell	79,302 -1,248	-2%	-$54.2K	0.38%	74
2017 Q4	$3.03M	Sell	80,550 -2,145	-3%	-$78.7K	0.29%	104
2017 Q3	$3.01M	Sell	82,695 -11,460	-12%	-$437K	0.32%	91
2017 Q2	$3.71M	Sell	94,155 -3,405	-3%	-$124K	0.42%	64
2017 Q1	$3.06M	Sell	97,560 -1,200	-1%	-$37.6K	0.34%	86
2016 Q4	$3.08M	Hold	98,760	–	–	0.36%	85
2016 Q3	$3.97M	Sell	98,760 -3,000	-3%	-$113K	0.5%	67
2016 Q2	$3.38M	Sell	101,760 -9,900	-9%	-$339K	0.45%	75
2016 Q1	$3.28M	Sell	111,660 -18,540	-14%	-$512K	0.46%	69
2015 Q4	$3.43M	Sell	130,200 -25,728	-16%	-$668K	0.5%	64
2015 Q3	$3.69M	Sell	155,928 -98,574	-39%	-$2.38M	0.58%	60
2015 Q2	$6.04M	Sell	254,502 -1,830	-0.7%	-$41.3K	0.88%	35
2015 Q1	$6.09M	Sell	256,332 -16,914	-6%	-$379K	0.88%	32
2014 Q4	$5.8M	Sell	273,246 -102,204	-27%	-$2.05M	0.87%	35
2014 Q3	$6.39M	Sell	375,450 -12,336	-3%	-$195K	1.05%	22
2014 Q2	$5.55M	Buy	387,786 +148,290	+62%	+$2.01M	0.9%	31
2014 Q1	$2.96M	Buy	+239,496	New	+$2.76M	0.5%	69

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Montag & Associates's EW Position: Q1 2026 in Review

Montag & Associates held its Edwards Lifesciences (EW) position steady in Q1 2026 at 45,996 shares worth $3.68M. The position accounts for 0.17% of the portfolio, ranked #121.

Montag & Associates first reported a position in EW in Q1 2014 and has held it in 49 quarters since. The position peaked at $14M in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Montag & Associates held 45,996 shares of Edwards Lifesciences worth $3.68M as of Q1 2026.
Montag & Associates left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.17% of Montag & Associates's portfolio in Q1 2026, its #121 holding.
Montag & Associates first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 49 quarters since.
Montag & Associates's Edwards Lifesciences position peaked at $14M in Q4 2021.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.